Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma

Abstract EN

Background.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most fatal malignancies due to its high morbidity and mortality.

DNA methylation exerts a vital part in the development of PDAC.

However, a mechanistic role of mutual interactions between DNA methylation and mRNA as epigenetic regulators on transcriptomic alterations and its correlation with clinical outcomes such as survival have remained largely uncovered in cancer.

Therefore, elucidation of aberrant epigenetic alteration in the development of PDAC is an urgent problem to be solved.

In this work, we conduct an integrative epigenetic analysis of PDAC to identify aberrant DNA methylation-driven cancer genes during the occurrence of cancer.

Methods.

DNA methylation matrix and mRNA profile were obtained from the TCGA database.

The integration of methylation and gene expression datasets was analyzed using an R package MethylMix.

The genes with hypomethylation/hypermethylation were further validated in the Kaplan–Meier analysis.

The correlation analysis of gene expression and aberrant DNA methylation was also conducted.

We performed a pathway analysis on aberrant DNG methylation genes identified by MethylMix criteria using ConsensusPathDB.

Results.

188 patients with both methylation data and mRNA data were considered eligible.

A mixture model was constructed, and differential methylation genes in normal and tumor groups using the Wilcoxon rank test was performed.

With the inclusion criteria, 95 differential methylation genes were detected.

Among these genes, 74 hypermethylation and 21 hypomethylation genes were found.

The pathway analysis revealed an increase in hypermethylation of genes involved in ATP-sensitive potassium channels, Robo4, and VEGF signaling pathways crosstalk, and generic transcription pathway.

Conclusion.

Integrated analysis of the aberrant epigenetic alteration in pancreatic ductal adenocarcinoma indicated that differentially methylated genes could play a vital role in the occurrence of PDAC by bioinformatics analysis.

The present work can help clinicians to elaborate on the function of differentially methylated expressed genes and pathways in PDAC.

CDO1, GJD2, ID4, NOL4, PAX6, TRIM58, and ZNF382 might act as aberrantly DNA-methylated biomarkers for early screening and therapy of PDAC in the future.